CN Mobile Logo

Search form


Dave Levitan

Dave Levitan

Posts by Author

Immediate treatment with androgen-deprivation therapy for men with asymptomatic non-curable prostate cancer did not have major effects on quality of life compared with delayed use, according to a phase III trial.

A Florida doctor was sentenced to serve nearly 6 years in prison for a variety of charges relating to her use of fraudulent medications to treat cancer patients.

Results of a phase III trial suggest that the combination of the contemporary oral fluoropyrimidine S-1 and cisplatin offers similar efficacy to 5-flourouracil and cisplatin in patients with chemotherapy-naive diffuse type adenocarcinoma of the gastroesophageal junction or stomach.

Patients with chronic myeloid leukemia in the blast phase pose a significant therapeutic challenge and have poor survival, even in the tyrosine kinase inhibitor era, according to a new study.

Low levels of cytotoxic stromal tumor-infiltrating lymphocytes are predictive of benefit derived from antibody- vs small molecule–based drug approaches to HER2-positive metastatic breast cancer.

Two different doses of cabazitaxel failed to show superiority with regard to overall survival over docetaxel as first-line treatment for patients with metastatic castration-resistant prostate cancer.

Olaparib tablet maintenance therapy provided a significant improvement in progression-free survival over placebo in patients with relapsed, platinum-sensitive ovarian cancer with a BRCA1/2 mutation.

Computed tomography (CT) screening for lung cancer could lead to increased rates of smoking cessation in a high-risk population, with this “teachable moment” extending even to those with negative scan results.

In patients with stage II to III urothelial carcinoma, bladder-preservation therapy was associated with poorer overall survival compared with radical cystectomy, according to a database study.

Breast cancer subtypes generally did not respond differently to radiotherapy following breast-conserving surgery, according to long-term follow-up of a randomized trial.


By clicking Accept, you agree to become a member of the UBM Medica Community.